Earnings summaries and quarterly performance for PURE BIOSCIENCE.
Research analysts who have asked questions during PURE BIOSCIENCE earnings calls.
Recent press releases and 8-K filings for PURE.
PURE Bioscience Reports Fiscal First Quarter 2026 Financial Results
PURE
Earnings
Revenue Acceleration/Inflection
New Projects/Investments
- PURE Bioscience reported net product sales of $707,000 for the fiscal first quarter ended October 31, 2025, an increase from $555,000 in the prior year period.
- The company's net loss decreased to $464,000 for Q1 2026, compared to a net loss of $689,000 for Q1 2025, resulting in a net loss per share of ($0.00) for Q1 2026, an improvement from ($0.01) in Q1 2025.
- PURE Bioscience noted continued momentum, expanding its PURE Control product in the produce industry and growing its SDC-powered sanitation technology in the transportation industry.
Dec 15, 2025, 9:05 PM
PURE Bioscience Reports Fiscal First Quarter 2026 Financial Results
PURE
Earnings
Revenue Acceleration/Inflection
New Projects/Investments
- PURE Bioscience reported net product sales of $707,000 for the fiscal first quarter ended October 31, 2025, an increase from $555,000 in the prior year period.
- The company's net loss for the fiscal first quarter ended October 31, 2025, was $464,000, an improvement from a net loss of $689,000 in the same period last year.
- Net loss per share for the fiscal first quarter ended October 31, 2025, was ($0.00), compared to ($0.01) for the fiscal first quarter ended October 31, 2024.
- PURE Bioscience is experiencing continued growth in sales of its PURE Control® solution for leafy greens and has expanded its SDC-powered sanitation technology into the transportation industry.
- The company is also working to roll out new membrane treatment solutions in the beverage and dairy industry.
Dec 15, 2025, 9:05 PM
PURE Bioscience Reports Fiscal Year 2025 Financial Results and Business Updates
PURE
Earnings
Product Launch
New Projects/Investments
- For the fiscal year ended July 31, 2025, net product sales increased by $243,000 to $2,198,000, up from $1,955,000 in the prior fiscal year.
- The company reported a net loss of ($2.4 million) for fiscal year 2025, an improvement from a net loss of ($3.4 million) in fiscal year 2024, with net loss per share at ($0.02) compared to ($0.03) in the previous year.
- Net cash used in operations decreased to ($2.0 million) for fiscal year 2025, down from ($2.5 million) in fiscal year 2024.
- PURE Bioscience expanded its core business by 14% and developed a new membrane treatment solution for the dairy and beverage industries, while also expanding its distribution network through partnerships with Hydrite Chemical Company and Bonsai.
- Total liabilities increased to $6,174,000 at July 31, 2025, from $3,682,000 at July 31, 2024, and the total stockholders' deficiency worsened to ($5,116,000) from ($2,864,000) over the same period.
Oct 29, 2025, 8:05 PM
PURE Bioscience Reports Fiscal 2025 Financial Results and Business Updates
PURE
Earnings
Product Launch
Revenue Acceleration/Inflection
- PURE Bioscience reported net product sales of $2,198,000 for the fiscal year ended July 31, 2025, an increase from $1,955,000 in the prior fiscal year.
- The company's net loss improved to ($2.4 million), or ($0.02) per share, for fiscal year 2025, compared to a net loss of ($3.4 million), or ($0.03) per share, in fiscal year 2024.
- PURE Bioscience launched a groundbreaking membrane treatment solution for dairy and beverage producers and expanded its distribution network through new agreements with Hydrite Chemical Company and Bonsai.
- Net cash used in operations for fiscal year 2025 was ($2.0 million), an improvement from ($2.5 million) in fiscal year 2024.
Oct 29, 2025, 8:05 PM
Quarterly earnings call transcripts for PURE BIOSCIENCE.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more